These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 26077004)
1. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004 [TBL] [Abstract][Full Text] [Related]
2. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481 [TBL] [Abstract][Full Text] [Related]
3. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806 [TBL] [Abstract][Full Text] [Related]
4. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843 [TBL] [Abstract][Full Text] [Related]
5. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422 [TBL] [Abstract][Full Text] [Related]
6. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416 [TBL] [Abstract][Full Text] [Related]
7. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409 [TBL] [Abstract][Full Text] [Related]
8. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. Langevin SM; Christensen BC Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702 [TBL] [Abstract][Full Text] [Related]
9. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao. Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651 [TBL] [Abstract][Full Text] [Related]
10. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325 [TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994 [TBL] [Abstract][Full Text] [Related]
12. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
13. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis. Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348 [TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. Zhang X; Wang Y; Gao N; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565 [TBL] [Abstract][Full Text] [Related]
15. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609 [TBL] [Abstract][Full Text] [Related]
16. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434 [TBL] [Abstract][Full Text] [Related]
17. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437 [TBL] [Abstract][Full Text] [Related]
18. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509 [TBL] [Abstract][Full Text] [Related]
19. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692 [TBL] [Abstract][Full Text] [Related]